

Application No. 10/031,509  
Paper Dated: November 3, 2003  
In Reply to USPTO Correspondence of November 3, 2003  
Attorney Docket No. 702-020040

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/031,509  
Applicant : Eric Paul Krenning et al.  
Filed : May 21, 2002  
Title : Inhibition of Renal Uptake of Molecules that are Potentially Damaging for the Kidney  
Group Art Unit : 1617  
Examiner : Shahnam J. Sharareh

ELECTION

MAIL STOP NON-FEE AMENDMENT  
Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This election is in response to the Office Action dated October 3, 2003. Applicants hereby elect the specie represented by the first compound's being lysine and the second compound's being arginine. All of pending claims 21-52 read upon the elected species.

The following clarification is intended to assist the Examiner and any docketing personnel who examine this Election. All of the pending claims 21-52 recite, or depend from a claim which recites, both a first compound and a second compound in the method and composition claims. The invention therefore never inheres in the selection of either a first

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 3, 2003.

Kimberly N. Weldon  
(Typed Name of Person Mailing Paper)

Signature

Date

*Kimberly N. Weldon* 11/03/2003

RECEIVED  
NOV 12 2003  
TECH CENTER 1600/2900

Application No. 10/031,509  
Paper Dated: November 3, 2003  
In Reply to USPTO Correspondence of November 3, 2003  
Attorney Docket No. 702-020040


compound or a second compound, so it would not conceptually be possible for applicant to elect a first compound without a second compound or vice versa. To the extent that the Office Action dated October 3, 2003 may imply, on page 2, that election is being requested between the species of the first and second compound, Applicants hope that the above explanation makes it clear that the elected specie of the generic invention must include one of each of the first and second compounds. For this reason, Applicants are electing the specie in which the first compound is lysine and the second compound is arginine. For this reason also, all of pending claims 21-52 read on the elected combination of lysine as the first compound and arginine as the second compound.

Examination and allowance of claims 21-52 are respectfully requested.

Pursuant to 37 C.F.R. § 1.48(b), there is no change in inventorship as a result of this election.

Respectfully submitted,  
WEBB ZIESENHEIM LOGSDON  
ORKIN & HANSON P.C.

By



Barbara E. Johnson  
Registration No. 31,198  
Attorney for Applicants  
700 Koppers Building  
436 Seventh Avenue  
Pittsburgh, PA 15219-1818  
Telephone: (412) 471-8815  
Facsimile: (412) 471-4094  
E-mail: webblaw@webblaw.com